title: Expression and functions of galectin-7 in human and murine melanomas.
abstract: The identification of galectin-7 as a p53-induced gene and its ability to induce apoptosis in many cell types support the hypothesis that galectin-7 has strong antitumor activity. This has been well documented in colon cancer. However, in some cases, such as breast cancer and lymphoma, its high expression level correlates with aggressive subtypes of cancer, suggesting that galectin-7 may have a dual role in cancer progression. In fact, in breast cancer, overexpression of galectin-7 alone is sufficient to promote metastasis to the bone and lung. In the present work, we investigated the expression and function of galectin-7 in melanoma. An analysis of datasets obtained from whole-genome profiling of human melanoma tissues revealed that galectin-7 mRNA was detected in more than 90% of biopsies of patients with nevi while its expression was more rarely found in biopsies collected from patients with malignant melanoma. This frequency, however, was likely due to the presence of normal epidermis tissues in biopsies, as shown our studies at the protein level by immunohistochemical analysis. Using the experimental melanoma B16F1 cell line, we found that melanoma cells can express galectin-7 at the primary tumor site and in lung metastasis. Moreover, we found that overexpression of galectin-7 increased the resistance of melanoma cells to apoptosis while inducing de novo egr-1 expression. Overexpression of galectin-7, however, was insufficient to modulate the growth of tumors induced by the subcutaneous injection of B16F1 cells. It also failed to modulate the dissemination of B16F1 cells to the lung.
authors: INRS-Institut Armand-Frappier, Laval, Québec, Canada.
authors: Katherine
authors: K
authors: Biron-Pain
authors: Andrée-Anne
authors: AA
authors: Grosset
authors: Françoise
authors: F
authors: Poirier
authors: Louis
authors: L
authors: Gaboury
authors: Yves
authors: Y
authors: St-Pierre
mesh_terms: D000818:Animals; D017209:Apoptosis; D001706:Biopsy; D051766:Early Growth Response Protein 1 / Q000235:genetics / Q000378:metabolism; D037161:Galectins / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D006801:Humans; D008156:Luciferases; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000556:secondary; D008545:Melanoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D009506:Nevus / Q000235:genetics* / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000556:secondary
chemical_list: D051766:Early Growth Response Protein 1; C486109:Egr1 protein, mouse; D037161:Galectins; C092525:LGALS7 protein, human; C490487:Lgals7 protein, mouse; D012333:RNA, Messenger; D008156:Luciferases
references: Curr Opin Oncol. 2006 Mar;18(2):189-96
references: 16462190
references: Cancer Res. 1975 Jan;35(1):218-24
references: 1109790
references: Oncogene. 2003 May 19;22(20):3152-61
references: 12789291
references: Cancer Res. 2005 Jun 15;65(12):5205-10
references: 15958565
references: J Proteome Res. 2009 Aug;8(8):3969-76
references: 19507834
references: Curr Opin Struct Biol. 2002 Oct;12(5):616-23
references: 12464313
references: Cancer Res. 2007 Mar 15;67(6):2824-9
references: 17363605
references: Nat Rev Cancer. 2005 Jan;5(1):29-41
references: 15630413
references: Proteomics. 2011 Nov;11(22):4411-21
references: 21919204
references: Front Biosci (Landmark Ed). 2012 Jan 01;17:438-50
references: 22201754
references: Dev Biol. 1995 Apr;168(2):259-71
references: 7729568
references: Ann Surg Oncol. 2006 Jul;13(7):999-1009
references: 16788763
references: Nat Rev Immunol. 2009 May;9(5):338-52
references: 19365409
references: Cancer Biol Ther. 2005 Sep;4(9):1018-29
references: 16251803
references: Curr Cancer Drug Targets. 2004 Feb;4(1):43-52
references: 14965266
references: Differentiation. 1998 Jul;63(3):159-68
references: 9697310
references: J Immunol. 2002 Nov 15;169(10):6036-47
references: 12421991
references: Clin Cancer Res. 2005 Oct 15;11(20):7234-42
references: 16243793
references: Cell Mol Life Sci. 2007 Jul;64(13):1679-700
references: 17497244
references: Mol Biol Cell. 2011 Apr;22(7):999-1013
references: 21289092
references: J Biol Chem. 1994 Aug 19;269(33):20807-10
references: 8063692
references: Apoptosis. 2005 Mar;10(2):267-75
references: 15843888
references: Mol Biol Cell. 2008 Dec;19(12):5541-9
references: 18829868
references: Neoplasia. 2005 Apr;7(4):303-11
references: 15967107
references: Am J Pathol. 2010 Jun;176(6):3023-31
references: 20382700
references: Apoptosis. 2007 Feb;12(2):411-21
references: 17191121
references: Pathol Res Pract. 2011 Apr 15;207(4):236-40
references: 21397408
references: Nature. 1997 Sep 18;389(6648):300-5
references: 9305847
references: N Engl J Med. 2006 Jul 6;355(1):51-65
references: 16822996
references: Cell Res. 2010 Apr;20(4):458-69
references: 20142842
references: Traffic. 2009 Oct;10(10):1405-13
references: 19650851
references: BMC Cancer. 2010 Jun 15;10:290
references: 20546628
references: Cell Mol Life Sci. 2012 Mar;69(5):783-91
references: 21833585
references: Cancer Res. 2004 Aug 15;64(16):5672-6
references: 15313906
references: Biochim Biophys Acta. 2004 Jul 6;1673(1-2):75-93
references: 15238251
references: Mod Pathol. 2002 Dec;15(12):1294-301
references: 12481010
references: J Biol Chem. 1995 Mar 17;270(11):5823-9
references: 7534301
references: Mol Carcinog. 1997 Oct;20(2):204-15
references: 9364210
references: Blood. 1998 Jan 15;91(2):623-9
references: 9427718
references: Clin Dev Immunol. 2012;2012:818214
references: 22778766